Clinical & Experimental Cardiology
Open Access

Abstract

Why is COVID-19 a Challenge for the Myocardium in Metabolic Syndrome Patients

Shawn Kant*, Frank W Sellke, Jun Feng and Anny Usheva

Cardiovascular disease is a significant long-term complication of uncontrolled hypertension, diabetes, and obesity, all of which co-occur in Metabolic Syndrome (MetS). The ongoing COVID-19 pandemic has highlighted the deleterious effects of MetS, as incidences of major cardiovascular complications such as thromboembolic events and myocardial infarction are significantly higher in patients with MetS. Several features of the myocardial tissue-level response to MetS, including a pro-inflammatory background, altered myocardial coagulation, and disturbances in the Renin- Angiotensin-Aldosterone system may explain the increased vulnerability of COVID-19 patients with MetS to deleterious cardiac effects.

Published Date: 2022-02-24; Received Date: 2022-01-24